GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors
Biology Open · 2026
DOI: 10.1242/bio.062358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology Open, 2026. Verfasst von Edlira Luca und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091 Zürich, Switze…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Pancreatic Neoplasms, Neuroendocrine Tumors, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss 3RCC, German Research Foundation, USZ.
Abstract (Originalsprache)
Pancreatic neuroendocrine tumors (pNETs) are rare tumors, often detected at advanced stages for which current therapies are mostly unsuccessful. Despite significant progress in the understanding of pathogenic molecular pathways, most single targeted treatments only slow disease progression while patients develop resistance due to compensatory mechanisms. To identify novel combination therapies, we assessed the effects of TNFα, insulin and GSK3 inhibition (GSK3i) in spheroids of the metastatic pNET model BON-1 on subcellular localization and activation of cell cycle components and apoptosis. While cyclin D1 and CDK4 and 6 (cyclin-dependent kinase) stainings, related protein levels and apoptosis were not affected or only weakly affected by single treatments, the combinatorial treatments acted synergistically to induce cell death, as assessed by cleaved caspase-3 immunopositivity. Protein levels of CDK4 and CDK6 were furthermore validated in primary pNET cultures. Compensatory mechanisms under the single treatments might include activation of CDK1/2 and the DNA damage response, as assessed by the activation of phospho-Chk2, since this was perturbed under the combinatorial treatments. Taken together, our work identifies combinatorial treatments that substantially reduce the viability of spheroidal BON-1 cultures and patient-derived primary cultures as potential novel therapies for the treatment of pNETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091 Zürich, Switzerland.
- Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
- Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS Center of Excellence), LMU University Hospital, LMU Munich, 81377 Munich, Germany.
- The LOOP Zurich-Medical Research Center, CH-8091 Zurich, Switzerland.
- ENETS Center of Excellence Zurich, University Hospital Zurich, CH-8091 Zurich, Switzerland.
ORCID-Profile: Edlira Luca
Förderung
- Swiss 3RCC
- German Research Foundation
- USZ
Zitieren
APA
Luca, E., Shapiro, I., Debaix, H., Zitzmann, K., Wang, K., Auernhammer, C. J., Beuschlein, F., Nölting, S., & Hantel, C. (2026). GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors. Biology Open. https://doi.org/10.1242/bio.062358
Vancouver
Luca E, Shapiro I, Debaix H, Zitzmann K, Wang K, Auernhammer CJ, et al. GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors. Biology Open. 2026. doi:10.1242/bio.062358
BibTeX
@article{Luca2026,
author = {Luca, Edlira and Shapiro, Igor and Debaix, Huguette and Zitzmann, Kathrin and Wang, Katharina and Auernhammer, Christoph J and Beuschlein, Felix and Nölting, Svenja and Hantel, Constanze},
title = {GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors},
journal = {Biology Open},
year = {2026},
doi = {10.1242/bio.062358}
}
EUVIMED